Alnylam Pharmaceuticals Inc. Reaches New 12-Month High at $65.83 (ALNY)
Alnylam Pharmaceuticals (NASDAQ:ALNY)’s share price reached a new 52-week high on Friday, Stock Ratings Network.com reports. The company traded as high as $65.83 and last traded at $63.99, with a volume of 407,044 shares traded. The stock had previously closed at $63.78.
A number of research firms have recently commented on ALNY. Analysts at Deutsche Bank raised their price target on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from $60.00 to $80.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at Needham & Company upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) to a “positive” rating in a research note to investors on Monday. They now have a $65.00 price target on the stock, up previously from $55.00. Finally, analysts at Leerink Swann raised their price target on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from $57.00 to $80.00 in a research note to investors on Monday. They now have an “outperform” rating on the stock. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $61.75.
Alnylam Pharmaceuticals has a 1-year low of $14.88 and a 1-year high of $64.90. The stock has a 50-day moving average of $53.77 and a 200-day moving average of $36.45. The company’s market cap is $4.034 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, August 8th. The company reported ($0.29) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.35) by $0.06. The company had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.99 million. During the same quarter last year, the company posted ($0.25) earnings per share. Alnylam Pharmaceuticals’s revenue was down 58.4% compared to the same quarter last year. On average, analysts predict that Alnylam Pharmaceuticals will post $-1.25 earnings per share for the current fiscal year.
Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.